UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000052179 |
|---|---|
| Receipt number | R000059525 |
| Scientific Title | Safety of Overconsumption of the Functional Food on Healthy Adult Males and Females. |
| Date of disclosure of the study information | 2023/09/18 |
| Last modified on | 2024/03/12 09:15:27 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Safety of Overconsumption of the Functional Food on Healthy Adult Males and Females.
Acronym
Safety of Overconsumption of the Functional Food on Healthy Adult Males and Females.
Scientific Title
Safety of Overconsumption of the Functional Food on Healthy Adult Males and Females.
Scientific Title:Acronym
Safety of Overconsumption of the Functional Food on Healthy Adult Males and Females.
Region
| Japan |
Condition
Condition
No
Classification by specialty
| Not applicable | Adult |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
The purpose of this study is to confirm the safety of taking the test food at 5 times the recommended daily intake for 4 weeks.
Basic objectives2
Safety
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Existence and its contents of side effects: expression number and expression rate of side effects (expression rate: number of cases/number of cases analyzed) (Week 0, Week 2, Week 4).
Key secondary outcomes
*Secondary outcomes
[1]Adverse events: number of cases and expression rate of adverse events (expression rate: number of cases/number of cases analyzed) (Week 0, Week 2, Week 4).
[2]Blood pressure, pulsation (Week 0, Week 2, Week 4).
[3]Weight, body fat percentage, BMI (Week 0, Week 2, Week 4).
[4]Hematologic test (Week 0, Week 2, Week 4).
[5]Blood biochemical test (Week 0, Week 2, Week 4).
[6]Urine analysis (Week 0, Week 2, Week 4).
[7]Doctor's questions (Week 0, Week 2, Week 4).
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Double blind -all involved are blinded
Control
Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
2
Purpose of intervention
Prevention
Type of intervention
| Food |
Interventions/Control_1
Oral intake of the test food (20 tablets in a day; 4 weeks).
Interventions/Control_2
Oral intake of the placebo food (15 tablets in a day; 4 weeks).
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 65 | years-old | > |
Gender
Male and Female
Key inclusion criteria
1)Males and females aged 20-64 years.
2)Individuals who are healthy and have no chronic physical disease including skin disorder.
3)Individuals whose written informed consent has been obtained.
4)Individuals who can come to the designated venue for this study and be inspected.
5)Individuals judged appropriate for the study by the principal.
Key exclusion criteria
1)Individuals using medical products.
2)Individuals who are patient or have a history of psychiatric disease, high blood pressure, diabetes, and hyperlipidemia.
3)Individuals who used a drug to treat a disease in the past 1 month (except temporal usage forpollenosis).
4)Individuals who have a history of serious hepatopathy, kidney damage, heart disease and hematological disease.
5)Individuals who are a patient or have a history of or endocrine disease.
6)Individuals whose BMI is less than 18.5kg/m2 and over 30kg/m2.
7)Individuals whose systolic and diastolic blood pressures are over 140mmHg and 90mmHg, respectively.
8)Individuals who donated blood over 200mL in the past 1 month or over 400mL in the past 3 months.
9)Individuals who experienced unpleasant feeling during blood drawing.
10)Individuals who are sensitive to the test food.
11)Individuals who habitually take the foods for specified health uses (FOSHU) or functional food (except for subjects who can stop consume them after informed consent).
12)Individuals who excessively take alcohol (expressed in an amount of alcohol: over 30g/day).
13)Individuals with possible changes of life style, such as conducting a long-term travel, during the test period.
14)Individuals who are or are possibly, or are lactating.
15)Individuals who participated in other clinical studies in the past 3 months.
16)Individuals who are or whose family is engaged in functional foods or cosmetics.
17)Individuals judged inappropriate for the study by the principal.
Target sample size
30
Research contact person
Name of lead principal investigator
| 1st name | Atsushi |
| Middle name | |
| Last name | Nakajima |
Organization
Ueno-Asagao Clinic
Division name
Head
Zip code
110-0015
Address
6F Kairaku Building 2-7-5 Higashiueno Taito-ku Tokyo 110-0015, JAPAN
TEL
+81-3-6240-1162
info@ueno-asagao.clinic
Public contact
Name of contact person
| 1st name | Ryoma |
| Middle name | |
| Last name | Shimizu |
Organization
TES Holdings Co., Ltd.
Division name
Administrative Department of Clinical Trials
Zip code
110-0015
Address
6F Kairaku Building 2-7-5 Higashiueno Taito-ku Tokyo 110-0015, JAPAN
TEL
+81-3-6801-8480
Homepage URL
r.shimizu@tes-h.co.jp
Sponsor or person
Institute
TES Holdings Co., Ltd.
Institute
Department
Personal name
Funding Source
Organization
KOBAYASHI Pharmaceutical Co., Ltd.
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Ueno-Asagao Clinic Ethical Review Committee
Address
6F Kairaku Building 2-7-5 Higashiueno Taito-ku Tokyo 110-0015, JAPAN
Tel
+81-3-6240-1162
jimukyoku@tes-h.co.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2023 | Year | 09 | Month | 18 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
30
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2023 | Year | 09 | Month | 05 | Day |
Date of IRB
| 2023 | Year | 09 | Month | 06 | Day |
Anticipated trial start date
| 2023 | Year | 09 | Month | 26 | Day |
Last follow-up date
| 2023 | Year | 10 | Month | 29 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2023 | Year | 09 | Month | 12 | Day |
Last modified on
| 2024 | Year | 03 | Month | 12 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000059525
